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Abstract
Aims: The purpose of this paper is to summarize the psychometric properties of four short
screening scales to assess problematic forms of cannabis use: Severity of Dependence Scale (SDS),
Cannabis Use Disorders Identification Test (CUDIT), Cannabis Abuse Screening Test (CAST) and
Problematic Use of Marijuana (PUM).
Methods: A systematic computer-based literature search was conducted within the databases of
PubMed, PsychINFO and Addiction Abstracts. A total of 12 publications reporting measures of
reliability or validity were identified: 8 concerning SDS, 2 concerning CUDIT and one concerning
CAST and PUM. Studies spanned adult and adolescent samples from general and specific user
populations in a number of countries worldwide.
Results: All screening scales tended to have moderate to high internal consistency (Cronbach's α
ranging from .72 to .92). Test-retest reliability and item total correlation have been reported for
SDS with acceptable results. Results of validation studies varied depending on study population and
standards used for validity assessment, but generally sensitivity, specificity and predictive power are
satisfactory. Standard diagnostic cut-off points that can be generalized to different populations do
not exist for any scale.
Conclusion: Short screening scales to assess dependence and other problems related to the use
of cannabis seem to be a time and cost saving opportunity to estimate overall prevalences of
cannabis-related negative consequences and to identify at-risk persons prior to using more
extensive diagnostic instruments. Nevertheless, further research is needed to assess the
performance of the tests in different populations and in comparison to broader criteria of cannabis-
related problems other than dependence.
Introduction
In recent years, trend data from consecutive cross-sec-
tional surveys in a variety of European countries have
shown a general increase in the prevalence of cannabis
use, particularly among the younger generations [1,2].
While, in most cases, consumption patterns remain exper-
imental or occasional [3,4], the increasing prevalence may
imply that a growing fraction of users will experience
adverse consequences on mental and physical health or
on a social level. Early identification of cannabis users at
risk for negative consequences is of considerable value
and the demand for appropriate and efficient screening
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instruments is increasing. A methodologically sound indi-
cator would be useful for both epidemiological and clini-
cal purposes. In the first case, screening scales could help
to identify risk factors in order to prevent cannabis-related
problems before they will cause serious health or other
adverse consequences in a large number of people. This
knowledge could guide the development and evaluation
of public health policies. In the second case, based on the
individual level of risk, users that have not yet entered the
treatment system could be allocated to brief early inter-
ventions. Moreover, screening scales in clinical settings
are a time and cost saving opportunity to identify at-risk
persons prior to using more extensive diagnostic instru-
ments.
Cannabis use has been associated with a range of adverse
effects that can be categorized in acute effects (e.g.
impaired attention, memory and psychomotor perform-
ance, road accidents), chronic health effects (e.g. bronchi-
tis, depression, dependence syndrome) and social
problems such as low educational attainment [5]. Further-
more, people with unstable health conditions have been
found to take cannabis to reduce symptoms of depression,
psychopathology or psychosocial distress [6,7]. But while
there are clear definitions and diagnostic criteria for can-
nabis dependence and abuse, there is no agreed-upon
concept for cannabis-related problems or so called "prob-
lem cannabis use" for individuals experiencing such
acute, chronic or social adverse consequences without ful-
filling the criteria for dependence. However, in recent
times, different researchers work on the elaboration of a
sub-threshold category "problem use" [8,9]. A number of
other indicators have been discussed, among them inten-
sity of use [10], consumption patterns (early morning
smoking, intake to facilitate sleeping, using pipes or other
facilities) or treatment demands [8], but to date none has
reached common acceptance.
Despite these conceptual difficulties, there are different
screening instruments used to measure negative conse-
quences of cannabis use [11]. The Severity of Dependence
Scale (SDS) [12] (see Appendix) is a 5-item scale that
measures the degree of psychological dependence specifi-
cally related to the individuals' feeling of impaired control
over and preoccupation and anxiety towards drug taking.
The Cannabis Use Disorder Identification Test (CUDIT)
[13] (see Appendix) screens for current cannabis use dis-
orders (abuse or dependence) according to DSM-IV,
whereas Problematic Use of Marijuana (PUM) [14] (see
Appendix) measures ICD-10 harmful use along with
problems in interpersonal relationships and psycho-phys-
ical functioning. Basically designed for adolescents or
young adults, the Cannabis Abuse Screening Test (CAST)
[15] (see Appendix) identifies patterns of cannabis use
leading to negative consequences on a social or health
level for the user himself or others. The major advantage
of these four instruments is that they are brief and easy to
administer. There are also other scales that measure can-
nabis-related problems, e. g. the Marijuana Screening
Inventory (MSI) [16], the Substance Dependence Severity
Scale (SDSS) [17], or the Cannabis Problems Question-
naire (CPQ) [18], but these are more extensive and too
time-consuming for epidemiological purposes. Thus, MSI
and CPQ consist of 31 and 29 items respectively taking
about 10 minutes to complete and the SDSS additionally
requires interviewer training and clinical experience.
In sum, there is considerable value in implementing
screening instruments that are capable of detecting canna-
bis dependence or cannabis-related problems. Several
short instruments have been developed and are available
for routine use in general populations as well as in clinical
settings. Despite of the high relevance, the number of
research in this field is rather scarce. This review summa-
rizes the psychometric properties of the four screening
scales SDS, CUDIT, CAST and PUM by using peer-
reviewed research to examine reliability and validity of
these instruments in different samples. This overview may
as well serve as a starting point for future research on the
assessment of cannabis-related problems by identifying
the major knowledge gaps.
Methods
Literature search
A systematic computer-based literature search was con-
ducted within the databases of PubMed, PsycINFO and
Addiction Abstracts. The four cannabis screening instru-
ments ("Severity of Dependence Scale" in combination
with "cannabis", as well as "Cannabis Abuse Screening
Test", "Cannabis Use Disorders Identification Test" and
"Problematic Use of Marijuana") were used as broad
search terms in order to gather peer-reviewed articles cit-
ing any use of these measures with no specific time frame.
This search was complemented by screening the World
Wide Web as well as the literature lists of retrieved publi-
cations for further references on the subject. Articles were
included if they evaluated at least one psychometric prop-
erty concerning reliability or validity. Articles were
excluded if the target questionnaires were used to only
measure the validity of another instrument. Articles were
also excluded if the instruments were used as screening
tools to identify cannabis-related problems but no data
on reliability or validity were presented.
The initial database search resulted in 64 publications
referring to the four cannabis screening instruments in the
title, the abstract or the keywords. These references were
downloaded to a reference database and abstracts were
screened to identify those relevant to the research ques-
tion. Exclusion of non-relevant papers (i. e. predomi-
nantly biochemical or pharmacological topics, studies on
the effects of cannabis use on different behavioural out-Substance Abuse Treatment, Prevention, and Policy 2008, 3:25 http://www.substanceabusepolicy.com/content/3/1/25
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comes), non-empirical papers and studies only using but
not validating the target instruments left eight publica-
tions for further consideration. Scanning the reference
lists and the World Wide Web led to the identification of
another four papers, adding up to a total of 12 selected
publications for this review.
The majority of papers addressed the SDS [19-26]. Two
studies evaluated the CUDIT [9,13]. CAST [15] and PUM
[14] were dealt with once. Studies spanned adult and ado-
lescent samples from seven different countries (Australia,
Germany, France, Brazil, New Zealand, Switzerland and
Poland). Samples from general and specific user popula-
tions were included. General characteristics of the selected
publications are displayed in Table 1.
Data extraction
Data extraction for this review followed predefined crite-
ria considered important in the evaluation of screening
instruments and was guided by a standardised documen-
tation sheet. As indicators of reliability, internal consist-
ency and test-retest reliability were considered. Construct
validity was evaluated by considering the scales' factor
structure as well as correlations with related constructs
(convergent validity). Concerning criterion validity, sensi-
tivity, specificity, positive predictive value (PPV) and neg-
ative predictive value (NPV) were included. Moreover,
results of Receiver Operating Characteristics (ROC) com-
puting cut-off values are reported.
For the evaluation of psychometric properties of screening
instruments it is important to differentiate between stud-
ies using samples from general populations and those
using specific user populations, as this directly affects sev-
eral psychometric indices. For example, the prevalence of
a disorder within the study population will influence the
ability of any screening test to detect it accurately. Thus, if
cannabis dependence is rare (in general population sam-
Table 1: Study characteristics
Author (year) Country Scale Assessment Mode Subjects Sampling 
(response rate)
General population samples
Steiner et al. 
(2008)
Germany SDS Dependence Questionnaire and 
telephone interview
456 adult cannabis users 
from population survey
Probabilistic population 
sample 
(45%, total sample)
Martin et al. (2006) Australia SDS Dependence Interview 100 adolescent cannabis 
users
Convenience sample
Kedzior et al. 
(2006)
Australia SDS Dependence Interview 69 adult study 
participants 
(healthy and 
schizophrenia patients)
Convenience sample
Kedzior et al. 
(2007)
Australia SDS Dependence Questionnaire 50 adult study 
participants 
(cannabis users)
Convenience sample
Okulicz-Kozaryn 
(2007)
Poland PUM Dependence Questionnaire and 
interview
1277 adolescent cannabis 
users
Snowball sample
Legleye et al. 
(2007)
France CAST Social and health 
problems
Questionnaire 123 cannabis users from 
school survey
Non-probabilistic 
school sample 
(85%, total sample)
Annaheim et al. 
(2008)
Switzerland CUDIT Chronic, acute and 
social problems, 
Motivation
Telephone interview 593 adolescent cannabis 
users from population 
survey
Probabilistic population 
sample 
(61.6%, total sample)
Specific user samples
Swift, Hall et al. 
(1998)
Australia SDS Dependence Interview 143 long-term cannabis 
users
Snowball sample
Swift, Copeland & 
Hall (1998)
Australia SDS Dependence Questionnaire and 
interview
200 long-term cannabis 
users
Convenience sample
Hides et al. (2007) Australia SDS Dependence Interview 153 in-patients with 
schizophrenia
Convenience sample
Ferri et al. (2000) Brazil SDS Dependence Interviewer-
administered 
questionnaire
347 regular users of 
cocaine
Convenience sample
Adamson & 
Sellman (2003)
New Zealand CUDIT Dependence Questionnaire and 
interview
53 out-patients with 
alcohol dependence 
(cannabis users)
Convenience sampleSubstance Abuse Treatment, Prevention, and Policy 2008, 3:25 http://www.substanceabusepolicy.com/content/3/1/25
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ples), a negative test will more likely indicate no disease
(high NPV) and a positive test will less likely indicate the
presence of the disease (low PPV) [27] than when it is
common, e.g. in samples of heavy cannabis users.
Results
Reliability
Internal consistency
General population
Five studies evaluated the internal consistency of the
screening scales in general population samples using
Cronbach's coefficient α (Table 2). Analyses suggest high
consistency of at least .72 for all four instruments, with
the highest value being for PUM [14] and the lowest value
for CUDIT [9]. On the other hand, item-total correlations
reported in two studies were only moderate varying
remarkably across items. Thus, kappa indices were low to
moderate for single pairs of items of the CAST [15]. In
addition, corrected item-total correlations of the CUDIT
were modest for most items, while inacceptable for items
2 (usual hours being stoned) and 9 (injuries) [9].
Specific user samples
Data from studies on specific cannabis users support high
internal consistency for the SDS (Table 2). This holds true
for samples of long-term cannabis users (at least 10 years
with weekly use) [26], schizophrenia patients (cannabis
use in the last 12 months) [20] and regular users of
cocaine [19]. Additionally, a study of out-patients with
alcohol dependence found good internal consistency for
the CUDIT [13]. Item-total correlations for nine out of ten
individual items were moderate to high, but could not be
calculated for item 9 (injuries) as there were no positive
responses to this question.
Test-retest reliability
General population
Only one paper concerning the SDS included temporal
reliability coefficients (Table 2) in an adolescents sample
from the general population [23]. Intra-class correlation
was satisfactory for both the scale's total score and the sin-
gle items over a one week period.
Specific user samples
Three day test-retest correlations of SDS were reported for
a sample of cocaine dependent patients [19]. Reliability
was good for the total score and moderate to good for the
single items of the scale.
Validity
Construct validity
General population
Factor analyses of the SDS, CAST and CUDIT have been
reported in four studies using adolescent and adult gen-
eral population samples [13,15,23,24]. In all cases analy-
ses resulted in a single factor solution that accounted for a
substantial portion of the total variance (53% and
57.6%). Individual factor loadings were moderate to high
(.41 to .87) for most items (except for CUDIT item 9 per-
forming very weakly).
Construct validity can also be assessed by measuring the
extent to which a scale correlates positively with other
measures that address the same construct (convergent
validity). Thus, moderate to high positive correlations (r =
.32 to .76) were found between the SDS total score and
frequency of cannabis use [23,24], amount of cannabis
use [24] and the number of DSM-IV dependence criteria
[23,24]. In addition, Legleye et al. [15] reported several
correlations of the CAST score with psycho-pathological
dimensions of the Problem Oriented Screening Instru-
ment for Teenagers (POSIT) [28] that measures psycho-
logical, physical and social health impairments. Students
with higher CAST scores reported worse physical and
mental health and more school problems.
Table 2: Reliability of cannabis screening instruments
Scale Study Internal consistency Test-retest reliability Item total correlation
General population samples
SDS Steiner et al. (2008) .80
SDS Martin et al. (2006) .83 .88 (total), .69 to .85 (items)
CAST Legleye et al. (2007) .81 [.74 for cannabis users] .26 to .56 (pairs of items)
CUDIT Annaheim et al. (2008) .72 .07 to .55
PUM Okulicz-Kozaryn (2007) .92
Specific user samples
SDS Swift, Hall et al. (1998) .72
SDS Hides et al. (2007) .81
SDS Ferri et al. (2000) .78 .74 (total), .46 to .76 (items)
CUDIT Adamson & Sellman (2003) .78 .44 to .77Substance Abuse Treatment, Prevention, and Policy 2008, 3:25 http://www.substanceabusepolicy.com/content/3/1/25
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Specific user samples
Factor structure of the SDS has also been examined in
samples which included participants with drug depend-
ence, psychosis and long-term cannabis dependence
[19,20,26]. Each showed that a single factor accounted for
a considerable portion of the total variance (48.4 –
56.8%). Consistently, all five items of the SDS had high
positive correlations on the factor score of greater than
.50. Convergent validity of the SDS was demonstrated by
reporting moderate to high significant correlations
between the scale's total score and the estimated quantity
of cannabis use, frequency of use and the number of DSM-
IV dependence criteria [19,21]. In the study of Swift, Hall
et al. [26] significant correlations between SDS and quan-
tity and frequency of use as well as age at first use and total
duration of use were not found. However, in their sample
of long-term cannabis users they could show a substantial
agreement between the SDS score and the respondents'
belief that their cannabis use caused problems (kappa =
.44).
Criterion validity
The selection of a specific external criterion for validation
is an important methodological consideration that influ-
ences the interpretation of the results. Since a common
definition of cannabis-related problems does not exist,
the current "gold standard" for assessing criterion validity
is to evaluate the screening instruments against DSM-IV
diagnosis of cannabis dependence [29]. Alternatively, it is
possible to cross-validate screening instruments against
broader concepts of problem use, like acute consequences
or psychosocial problems related to cannabis consump-
tion.
General population
Most studies reporting measures of criterion validity used
a dependence diagnosis (DSM-IV or ICD-10) retrieved
from a clinical interview as an external criterion. Alto-
gether, SDS and PUM were found to have a good ability to
discriminate between dependent and non-dependent
individuals, correctly classifying at least 85% of cases
(Table 3). Though different cut-off points have been
reported depending on the study sample, all evaluations
revealed high values of specificity and usually lower, but
still high, levels of sensitivity. As an exception, the study
by Steiner et al. showed much higher sensitivity than spe-
cificity [24]. Moreover, the positive predictive power of
the SDS is very low.
Table 3: Criterion validity of cannabis screening instruments
Scale Study Criterion Cut-off Sensitivity Specificity Positive 
predictive 
value
Negative 
predictive 
value
Area under 
the curve
General population samples
SDS Steiner et al. 
(2008)
DSM-IV 
dependence
2
[men: 4]
93.6% [81.0%] 74.0% [86.9%] 28.8% 99.0% .92
SDS Martin et al. 
(2006)
DSM-IV 
dependence
4 65.1% 94.3% .85
SDS Kedzior et al. 
(2007)
Any DSM-IV or 
ICD-10 diagnosis
72.7%a 96.4%a 94.1%a 81.8%a
PUM Okulicz-
Kozaryn (2007)
ICD-10 
dependence
2 80.9% 87.5% 86.6% 82.2% .91
CAST Legleye et al. 
(2007)
POSITc 4 92.9% 81.4% 45.8%b 96.5%b .92
CUDIT Annaheim et al. 
(2008)
Use at school 7 71.1% 64.2% 14.1%b 96.4%b .74
Use and drive 5 66.7% 58.9% 29.6%b 83.3%b .63
Depression 5 57.8% 50.4% 43.8%b 64.2%b .57
Use to cope 5 75.0% 58.9% 49.2%b 81.6%b .76
Self-evaluation 7 71.3% 69.7% 36.6%b 91.0%b .77
Specific user samples
SDS Swift, Copeland 
& Hall (1998)
DSM-III-R 
dependence
3 64.0% 82.0% .77
SDS Hides et al. 
(2007)
DSM-IV 
dependence
2 86.0% 83.0% 83.0% 86.0%
CUDIT Adamson & 
Sellman (2003)
DSM-IV 
dependence
8 73.3% 94.7% 84.6% 90.0% .87
a Computed by the authors. b Received on request
c Problem Oriented Screening Instrument for Teenagers [28] measures psychological, physical and social problems.Substance Abuse Treatment, Prevention, and Policy 2008, 3:25 http://www.substanceabusepolicy.com/content/3/1/25
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Two studies have examined the scales for possible sex and
age differences. PUM seems equally appropriate for males
and females as well as for different age groups [14]. The
original cut-off score could also be maintained in a sub-
sample for which cannabis was the first choice drug.
Validity of the SDS did also not differ between several ages
[24]. However, choosing a higher cut-off increased sensi-
tivity and specificity for males as compared to females.
In contrast to previous studies, two projects did not use
DSM-IV or ICD-10 diagnoses as the "gold standard" to
compare with but some broader concepts of problem use.
Thus, the drug abuse section of the POSIT questionnaire
was used to cross-validate CAST scores [15] and several
single-item indicators of cannabis-related problems were
used to validate CUDIT [9]. In this context, CAST proved
to be effective when screening for high risks of abuse
showing high values of sensitivity, specificity and predic-
tive power (Table 3). CUDIT revealed quite favourable
levels of sensitivity and lower, but in most cases still
acceptable, specificity. As in the Steiner et al. study [24],
positive predictive value of the scale was low due to the
low base rate of cannabis use in the overall sample.
Specific user samples
Three papers reported the validity of the SDS und CUDIT
against DSM diagnoses in cannabis users (Table 3). Again,
different cut-off points were found depending on the
study sample. Sensitivity, specificity and predictive power
of the SDS are comparable to those reported in general
population samples [20,25]. CUDIT performed better in
an alcohol-dependent sample [13] as compared to the
general population study mentioned above. There are no
studies evaluating possible subgroup differences (sex or
age) or applying other external criteria than dependence
diagnoses.
Discussion
Aim of this paper was to summarize the psychometric
properties of four short screening scales to assess canna-
bis-related disorders or problems (SDS, CUDIT, CAST,
PUM). A total of 12 studies from a variety of countries
using diverse samples from general and specific user pop-
ulations have been identified. While the SDS has been
well studied in different samples, research on the other
three instruments is limited. Psychometric properties of
all scales varied depending on the study population and
standards used for validity assessment, and therefore,
comparisons between scales and studies are limited.
The results of our review suggest that the SDS is a valid
diagnostic instrument for both general and specific user
populations. Its diagnostic potential as a screen for iden-
tifying individuals with symptoms of substance use
dependence has been shown not only for cannabis but
also for cocaine [30], amphetamines [31], benzodi-
azepines [32], and most recently alcohol [33]. However, a
standard diagnostic cut-off does not exist. The cut-off
points reported vary between 2 and 4 across different
studies. Specific analyses for sub-populations (different
age groups, sex) also revealed differences. This implies
that cut-off scores need to be defined independently for
different populations.
The available evidence on psychometric properties comes
primarily from studies evaluating SDS against cannabis
dependence diagnoses. Only two studies used other crite-
ria, like psychosocial consequences or a self-evaluation of
problem cannabis use [9,15]. Both approaches have their
individual benefits. The major advantage in using the
"gold standard" cannabis dependence is to rely on an
internationally acknowledged construct with predefined
criteria and operationalizations. On the other hand, refer-
ring to criteria other than dependence symptoms allows a
broader view on cannabis-related problems that might be
helpful in detecting people who experience acute or
chronic negative consequences without fulfilling the crite-
ria for dependence.
The instruments most recently evaluated [9,15] assess
cannabis-related problems namely social or health prob-
lems (CAST) and in addition motivational aspects of can-
nabis use (CUDIT). The psychometric properties of the
CAST are comparable to the SDS, while the performance
of the CUDIT is moderate. In particular, two items – can-
nabis related injury (item 9) and usual hours being stoned
(item 2) – performed very weakly in tests of reliability and
construct validity. These questions need to be revised or
deleted from the scale especially as there are hardly posi-
tive responses in the samples studied.
There are a number of methodological considerations
concerning the evaluation of screening scales that, inde-
pendent of the assessment criteria, need to be further elu-
cidated. First, the choice of an optimal cut-off largely
depends on the context of the study and the specific task
at hand [34]. For example, using the SDS as a screening
tool for cannabis dependence in a clinical setting, it may
be preferable to maximize the ability to detect people who
are at risk for dependence (i. e. use a lower cut-off) at the
expense of decreased specificity. On the other hand, it
may be more important to minimize costs, i.e. to avoid
selecting people for treatment who do not need it. In this
case, it may be more appropriate to use a higher cut-off
with increased specificity and decreased sensitivity. In
research settings, where the main interest is to estimate
prevalence, the optimal approach would be to take a value
that offers the best balance between sensitivity and specif-
icity.
Second, a clear understanding of the way in which diag-
nostic accuracy may be affected by the population toSubstance Abuse Treatment, Prevention, and Policy 2008, 3:25 http://www.substanceabusepolicy.com/content/3/1/25
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which a screening test is applied is required. As noted ear-
lier, the prevalence of a cannabis-related disorder or prob-
lem will affect the ability of any screening test to detect it
accurately. Predictive power will be low when the preva-
lence is low, even if sensitivity and specificity of the instru-
ment are high [27,35]. On population level, this effect
may lead to a non-negligible overestimation of the preva-
lence. For example, positive predictive values of SDS and
CUDIT tested in truly probabilistic samples [9,24] were
rather low with 14.1% to 49.2%. Other studies used tar-
geted samples of preselected cannabis users (e.g. recruited
through magazines, or snowball sampling) [14,22,23]
which resulted in higher positive predictive values up to
94.1%.
Third, the eligibility of dependence diagnoses as the "gold
standard" itself needs to be discussed. There is still a con-
troversy about the way in which the drug (and especially
the cannabis) dependence syndrome should be opera-
tionalized in future diagnostic systems like DSM-V, which
is currently being prepared. For example, it has been
argued that the rule of three criteria that has been defined
for alcohol and opiate dependence may be over-inclusive
for cannabis [36,37]. Others emphasize psychological
components or behavioural indicators of dependence
[37] or propose dimensional equivalents for the so far cat-
egorically defined substance use disorders [38].
There has been some discussion on the applicability of
screening instruments in different settings (research vs.
clinical). For example, in the original publication Gossop
et al. [12] explicitly recommend the SDS for research pur-
poses and not for clinical use. In recent times however,
increasing evidence suggests its utility as a clinical and
research tool [33]. Screens can be specifically useful in
clinical settings as their results can determine further steps
in the individual assessment or treatment planning. Those
patients with a positive screening result can be referred to
more extensive diagnostic assessments of cannabis
dependence (for example CIDI). Patients, for whom the
CIDI assessment does not confirm the screening result,
may still experience negative consequences from their
cannabis use. These individuals do not need full treat-
ment but may be referred to brief interventions. In the
case of cannabis, further studies need to assess the per-
formance of screening scales in different clinical settings.
In general, users of screening tests should be cautious in
addressing the identified individuals as problem cannabis
users without considering the particular problems the test
is referring to. On the other hand, depending on the pur-
pose a screen is used for (e.g., prevalence estimation, clin-
ical assessment) the recipients of the results should be
made aware of the psychometric properties of the test. The
choice of the cut-off determines the proportion of targeted
but not identified individuals as well as the proportion of
individuals who although identified do not fulfil the ref-
erence criteria.
Further research and developments regarding screening
instruments are required in order to improve the assess-
ment of cannabis-related problems. As mentioned earlier,
at least CUDIT may need some revision because of the
very weak performance of several items in psychometric
analyses. Additional research should evaluate the useful-
ness of screening scales in different settings and for sub-
populations of particular interest. With regard to adoles-
cents, current projects in France and Spain investigate the
performance of CAST in different samples. In Australia,
attempts are made to develop a new screen intended to
identify current and potential problems related to canna-
bis use on population level.
Conclusion
Identifying people who show symptoms of dependence or
experience other acute or chronic problems due to canna-
bis use is important both in the general population and
the clinical setting. In general, all four screening scales
included in our review yielded satisfactory measures of
reliability and validity. Furthermore, these tests are brief
and easy to administer and have been used in a variety of
populations. The SDS is a valid and viable instrument for
screening cannabis dependence. It may be used as an
adjunct to more extensive diagnostic interments. Some
progress has been made in the development of short
instruments to assess negative consequences of cannabis
use other than dependence. Research questions remain
with regard to the performance of the instruments in rep-
resentative population samples and in comparison to
broader criteria of cannabis-related problems.
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Appendix
Severity of Dependence Scale (SDS)
During the past year...
(1) Did you think your use of cannabis was out of control?
never/almost never (0) – sometimes (1) – often (2) –
always/nearly always (3)Substance Abuse Treatment, Prevention, and Policy 2008, 3:25 http://www.substanceabusepolicy.com/content/3/1/25
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(2) Did the prospect of missing a dose of cannabis makes
you anxious or worried?
never/almost never (0) – sometimes (1) – often (2) –
always/nearly always (3)
(3) Did you worry about your use of cannabis?
never/almost never (0) – sometimes (1) – often (2) –
always/nearly always (3)
(4) Did you wish you could stop the use of cannabis?
never/almost never (0) – sometimes (1) – often (2) –
always/nearly always (3)
(5) How difficult did you find it to stop, or go without
cannabis?
Not difficult (0) – quite difficult (1) – very difficult (2) –
impossible (3)
From: Gossop M, Darke S, Griffith P, Hando J, Powis B,
Hall W, Strang J in Addiction 1995, 90(5), 607 – 614.
Cannabis Use Disorders Identification Test (CUDIT)
Over the past 6 months...
(1) How often did you use cannabis?
Never (0) – monthly or less (1) – 2 – 4 times a month (2)
– 2 – 3 times a week (3) – 4 or more times a week (4)
(2) How many hours were you "stoned" on a typical day
when you had been using cannabis?
1 or 2 (0) – 3 or 4 (1) – 5 or 6 (2) – 7 to 9 (3) – 10 or more
(4)
(3) How often were you "stoned" for 6 or more hours?
Never (0) – less than monthly (1) – monthly (2) – weekly
(3) – daily or almost daily (4)
(4) How often did you find that you were not able to stop
using cannabis once you had started?
Never (0) – less than monthly (1) – monthly (2) – weekly
(3) – daily or almost daily (4)
(5) How often did you fail to do what was normally
expected from you because of using cannabis?
Never (0) – less than monthly (1) – monthly (2) – weekly
(3) – daily or almost daily (4)
(6) How often did you needed to use cannabis in the
morning to get yourself going after a heavy session of
using cannabis?
Never (0) – less than monthly (1) – monthly (2) – weekly
(3) – daily or almost daily (4)
(7) How often did you have a feeling of guilt or remorse
after using cannabis?
Never (0) – less than monthly (1) – monthly (2) – weekly
(3) – daily or almost daily (4)
(8) How often have you had a problem with your mem-
ory or concentration after using cannabis?
Never (0) – less than monthly (1) – monthly (2) – weekly
(3) – daily or almost daily (4)
(9) Have you or someone else been injured as a result of
your use of cannabis?
No (0) – yes (4)
(10) Has a relative, friend or doctor or other health worker
been concerned about your use of cannabis or suggested
you cut down?
No (0) – yes (4)
From: Adamson SJ, Sellman JD in Drug Alcohol Rev 2003,
22, 309 – 315.
Cannabis Abuse Screening Test (CAST)
(1) Have you ever smoked cannabis before midday?
never (0) – rarely (0) – from time to time (0) – fairly often
(1) – very often (1)
(2) Have you ever smoked cannabis when you were
alone?
never (0) – rarely (0) – from time to time (0) – fairly often
(1) – very often (1)
(3) Have you ever had memory problems when you
smoked cannabis?
never (0) – rarely (0) – from time to time (0) – fairly often
(1) – very often (1)
(4) Have friends or members of your family ever told you
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never (0) – rarely (0) – from time to time (0) – fairly often
(1) – very often (1)
(5) Have you ever tried to reduce or stop your cannabis
use without succeeding?
never (0) – rarely (0) – from time to time (0) – fairly often
(1) – very often (1)
(6) Have you ever had problems because of your use of
cannabis (argument, fight, accident, bad result at school,
etc.)?
never (0) – rarely (0) – from time to time (0) – fairly often
(1) – very often (1)
From: Legleye S, Karila L, Beck F, Reynaud M in J Subst Use
2007, 12(4), 233 – 242.
Problematic Use of Marijuana (PUM)
(1) Have you ever skipped school classes or came late to
school because of cannabis use?
Yes – no
(2) Have you had a serious argument with family mem-
bers because of your cannabis use?
Yes – no
(3) Have you had a serious argument with friends because
of your cannabis use?
Yes – no
(4) Have you ever bought cannabis yourself?
Yes – no
(5) Do you have more and more problems In studying
and understanding new information?
Yes – no
(6) Have you ever used cannabis when you were alone?
Yes – no
(7) Do you often feel desire for cannabis?
Yes – no
(8) Have you ever spent so much money on cannabis that
you had to resign from other things or activities?
Yes – no
From: Okulicz-Kozaryn K in Postepy Psychiatrii i Neurologii
2007, 16(2),105 – 111. Translation by the original
author.
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